期刊文献+

雷公藤内酯醇联合顺铂对荷膀胱癌T24细胞裸鼠免疫功能及血管生长作用的影响 被引量:3

Effect of triptolide combined with cisplatin on immune function and angiogenesis of bladder cancer (T24) cells - bearing nude mice
原文传递
导出
摘要 目的观察雷公藤内酯醇联合顺铂对荷膀胱癌T24细胞裸鼠免疫功能及血管生长作用的影响。方法建立荷膀胱癌T24细胞小鼠模型18只,随机分为对照组、顺铂组、联合组各6只,分别腹腔注射5d0.9%氯化钠溶液、顺铂、雷公藤内酯醇+顺铂。采用流式细胞仪检测腹腔巨噬细胞异硫氰酸荧光素(FITC)-右旋糖酐(dexran)阳性率,采用酶联免疫吸附试验法(ELISA)检测腹腔巨噬细胞白细胞介素-1(IL-1)、肿瘤坏死因子-α(TNF-α)表达水平,采用免疫组织化学染色法检测荷瘤裸鼠肿瘤组织的微血管密度(MVD)、血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)的表达水平。结果巨噬细胞吞噬能力:联合组小鼠腹腔巨噬细胞FITC-dexran、CD11b.FITC、CD68-FITC阳性率明显高于顺铂组[(11.74±1.25)%比(7.24±0.84)%,(33.33±3.46)%比(21.84±2.45)%,(33.89±4.12)%比(20.52±2.32)%,t=9.639~7.319,P〈0.05];免疫功能:联合组IL-1、TNF-α表达水平明显高于顺铂组[(40.92±3.86比26.05±3.01)pg/ml,(55.78±6.25比38.42±5.26)pg/m1(t=5.201~7.441,P〈0.05];血管生长因子:联合组VEGF、bFGF、MVD表达水平明显低于顺铂组(1.24±0.48比1.88±0.52,0.88±0.43比1.51±0.56,3.11±1.49比8.15±3.00,t=2.186~3.686。P〈0.05)。结论雷公藤内酯醇联合顺铂能够提高荷膀胱癌T24细胞小鼠腹腔巨噬细胞的吞噬功能及免疫功能,下调VEGF和bFGF的表达水平,抑制肿瘤细胞的生长增殖。 Objective To Study the effect of triptolide combined with cisplatin on immune function and angiogenesis of bladder cancer (T24) cells - bearing nude mice. Methods Eighteen bladder cancer (T24) cells -bearing nude mice were divided into control group, cisplatin group, and combination group, respectively given intraperitoneal injection of 0. 9% sodium chloride solution, eisplatin, and triptolide ± eisplatin. Flow eytometry was used to detect fluoresceine isothiocyanate ( FITC ) - dexran positive rate of abdominal macrophages, enzyme linked immunosorbent assay (ELISA) to determine interleukin (IL) -1 and tumor necrosis factor-ct (TNF- α) expression levels in the abdominal macrophages, and immunohis- tochemieal staining to examine vascular endothelial growth factor (VEGF) , basic fibroblast growth factor (bFGF) and microvessel density (MVD) expression levels. Results The positive rate of FITC - dexran, CD11 b- FITC, and CD68 -FITC in abdominal macrophages of combination group was significantly higher than that in eisplatin group [ ( 11.74 ± 1.25) % vs. (7.24 ± 0. 84) %, (33.33 ± 3.46) % vs. (21.84 ± 2.45)%, and (33.89 ±4. 12)% vs. (20. 52 ±2. 32)%1 (t=9.639-7.319,P〈0.05). The IL-1 and TNF -α expression levels in combination group were significantly higher than those in cisplatin group [(40.92±3.86) vs. (26.05 ±3.01) pg/ml, and (55.78 ±6.25) vs. (38.42 ±5.26) pg/ml] (t= 5. 201 -7.441 ,P 〈0. 05). The VEGF, bFGF, and MVD expression levels in combination group were sig- nificantly lower than those in cisplatin group ( 1.24 ± 0.48 vs. 1.88 ± 0. 52, 0. 88 ± 0. 43 vs. 1.51 ± 0.56, and 3.11±1. 49 vs. 8.15 ±3.00) (t=2.186-3.686,P〈0.05).Conclusion Triptolide com- bined with eisplatin can improve phagocytosis function and immune function of abdominal macrophages in bladder cancer (T24) cells - bearing nude mice, and reduce VEGF and bFGF expression levels, and then inhibit growth and proliferation of tumor cells.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2016年第6期1448-1450,共3页 Chinese Journal of Experimental Surgery
关键词 膀胱肿瘤 雷公藤内酯醇 顺铂 免疫功能 血管生长因子 Urinary bladder neoplasms Triptolide Cisplatin Immune function Vascular growth factors
  • 相关文献

参考文献4

二级参考文献34

  • 1李国光,邱书明,林崇文,张富鑫.EHF毫米波辐照对受化疗处理期小鼠造血系统的保护作用[J].中华物理医学杂志,1995,17(3):175-177. 被引量:11
  • 2Chun ZHANG Guo-hui CUI Fang LIU Qiu-ling WU Yan CHEN.Inhibitory effect of triptolide on lymph node metastasis in patients with non-Hodgkin lymphoma by regulating SDF-1/CXCR4 axis in vitro[J].Acta Pharmacologica Sinica,2006,27(11):1438-1446. 被引量:14
  • 3Xin Yuan Liu~(1,2) ~1Institute of Biochemistry and Cell Biology,Shanghai Institutes for Biological Sciences,Chinese Academy of Sciences,320 Yue Yang Road,Shanghai 200031,China,~2Xinyuan Institute of Medicine and Biotechnology,School of Life Science,Zhejiang Sci-Tech University,Hangzhou 310018,China.Targeting Gene-Virotherapy of Cancer and its prosperity[J].Cell Research,2006,16(11):879-886. 被引量:32
  • 4李庆,翟志敏,黄文洲,徐静玮,余南生,骆云鹏.流式细胞术评价极高频电磁波对化放疗肿瘤患者免疫细胞表达的影响[J].免疫学杂志,2007,23(4):429-432. 被引量:5
  • 5张之南,沈悌.血液病诊断及疗效标准[M].第3版.北京:科学出版社,1999:173-175.
  • 6Muggia FM,Braly PS,Brady MF,et al.Phase Ⅲ randomized study of cisplatin versus pacli-taxel versus cisplatin and paclitaxel in patients with suboptimal stage Ⅲ or Ⅳ ovarian cancer:A Gynecologic Oncology Group study[J].J Clin Oncol,2000,18:106-115.
  • 7Ozols RF,Bundy BN,Greer BE,et al.Gynecologic Oncology Group.Phase Ⅲ trial of carbo-platin and paclitaxel compared with cisplatin andpaclitaxel in patients with optimally resected stage Ⅲ ovarian cancer:A Gynecologic Oncology Group study[J].J Clin Oncol,2003,21:3194 -3200.
  • 8Alberts DS,Green S,Hannigan EV,et al.Improved therapeutic index of carboplatin plus cyclo-phosphamide versus cisplatin plus cyclophosphamide:final report by the Southwest Oncology Group of a phase Ⅲ randomized trial in stages Ⅲ and Ⅳ ovarian cancer[J].J Clin Oncol,1992,10:706-717.
  • 9Gadducci A,Conte PF.Intraperitoneal chemotherapy in the management of patients with ad-vanced epithelial ovarian cancer:a critical review of the literature[J].Int J Gynecol Cancer,2008,18:943-953.
  • 10Elit L,Oliver TK,Covens A,et al.Intraperitoneal chemotherapy in the first-line treatment of women with stage Ⅲ epithelial ovarian cancer:a systematic review with metaanalyses[J].Cancer,2007,109:692-702.

共引文献18

同被引文献31

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部